22nd Century Group's reduced nicotine bet falls flat with investors
Seeking Alpha News (Tue, 7-Apr 9:26 AM ET)
22nd Century Group's reduced nicotine bet falls falls flat with investors
Seeking Alpha News (Tue, 7-Apr 9:26 AM ET)
Globe Newswire (Tue, 7-Apr 8:00 AM ET)
22nd Century Group Reports Fourth Quarter and Full Year 2025 Financial Results
Globe Newswire (Thu, 26-Mar 6:00 AM ET)
22nd Century Group to Announce Fourth Quarter and Full Year 2025 Results on March 26, 2026
Globe Newswire (Mon, 23-Mar 8:00 AM ET)
22nd Century Group Reports Continued Early Sales Momentum for VLN Cigarette Products
Globe Newswire (Mon, 23-Feb 5:07 PM ET)
22nd Century Group Preliminarily Reports Fourth Quarter and Full Year 2025 Financial Results
Globe Newswire (Fri, 20-Feb 4:15 PM ET)
22nd Century CEO & Chairman Larry Firestone Provides 2025 Year-in-Review Letter to Stockholders
Globe Newswire (Thu, 15-Jan 9:00 AM ET)
22nd Century to Participate in the Needham Annual Growth Conference January 16, 2026
Globe Newswire (Mon, 12-Jan 4:30 PM ET)
Market Chameleon (Wed, 29-Oct 7:30 AM ET)
22nd Century Group Inc is a tobacco products company that enables cigarette smokers to take control of their consumption of nicotine, the addictive drug in cigarettes. The company manufactures and distributes the only combustible tobacco products containing minimally or non-addictive levels of nicotine. The Company has organized its business as a single reportable segment: tobacco, as it operates and derives all revenues from its tobacco operations and products.
22Nd Century Group trades on the NASDAQ stock market under the symbol XXII.
As of April 10, 2026, XXII stock price declined to $2.01 with 14,644 million shares trading.
XXII has a beta of 4.21, meaning it tends to be more sensitive to market movements. XXII has a correlation of 0.04 to the broad based SPY ETF.
XXII has a market cap of $1.33 million. This is considered a Sub-Micro Cap stock.
Last quarter 22Nd Century Group reported $4 million in Revenue and -$5.89 earnings per share. This fell short of revenue expectation by $-513,000 and missed earnings estimates by -$3.79.
In the last 3 years, XXII traded as high as $561,763.20 and as low as $.67.
XXII has underperformed the market in the last year with a price return of -91.8% while the SPY ETF gained +25.2%. However, in the short term, XXII had mixed performance relative to the market. It has outperformed in the last 3 months, returning +121.6% vs -1.8% return in SPY. But in the last 2 weeks, XXII shares have been beat by the market, returning -31.6% compared to an SPY return of +5.3%.
XXII support price is $1.88 and resistance is $2.18 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that XXII shares will trade within this expected range on the day.